The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment or above of Pancreatic Cancer patients with a KRAS G12C mutation. This is a multi-center, single-arm, open-label study. The study results will be used to submit NDA (New Drug Application) for pancreatic cancer.

"The pivotal study of pancreatic cancer is the second approved registrational study after non-small cell lung cancer", said gastrointestinal oncology expert Dr. Andrea Wang-Gillam, the Chief Medical Officer of Jacobio, "We hope to work with clinical study investigators to jointly advance the clinical trials and strive to bring more treatment options to cancer patients with KRAS G12C-mutated as soon as possible."

Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently. The five-year overall survival rate is only 5%. About 90% of pancreatic cancer patients have different types of KRAS mutations. Besides KRAS G12C inhibitor glecirasib, Jacobio is developing KRAS^multi, KRAS G12D and other projects, which are expected to benefit more pancreatic cancer patients.